Lupin Limited has launched an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States, effective October 24, 2025. This medication is used for the chronic management of patients with urea cycle disorders (UCDs). Lupin is a global pharmaceutical leader committed to enhancing patient health outcomes.
US Market Expansion
Lupin Limited (Lupin) announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States on October 24, 2025. This launch further expands Lupin’s presence in the US market.
Therapeutic Use
The oral liquid is indicated for the chronic management of patients with urea cycle disorders (UCDs). These are specific cases where UCDs cannot be adequately managed through dietary protein restriction and/or amino acid supplementation alone.
Lupin’s Commitment
With its headquarters in Mumbai, India, Lupin distributes its products in over 100 markets. The company focuses on pharmaceutical products including generics, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin is committed to improving patient health outcomes through its subsidiaries. The company has 15 state-of-the-art manufacturing sites and 7 research centers globally.
Source: BSE